

# The finances of Association Mieux Prescrire: 2024 annual report

Association Mieux Prescrire (AMP), the legal entity that publishes Prescrire's publications and educational programmes, is a non-profit organisation governed by the French law of 1901. This is the legal structure best suited to preserving Prescrire's independence among those available in France as of 2025. It also aligns with our goal of standing with healthcare professionals to serve patients' interests.

Prescrire relies on the sales of these publications and educational programmes to fund its work. It accepts no advertising, grants or subsidies, and has no sponsors or shareholders. Our subscribers are our sole source of income and fund everything we do. As a non-profit organisation engaged in commercial activities, AMP is subject to the regulations governing taxation and employment in France, and its accounts are approved by an independent auditor. Every year, AMP submits its budget and actual figures to its board and general assembly for approval. A summary of AMP's annual financial report is freely available every year on its websites [prescrire.org](http://prescrire.org) and [english.prescrire.org](http://english.prescrire.org).

**The financial stability required...** The 2023-2024 fiscal year ran from 1 September 2023 to 31 August 2024. In a difficult climate that affected a great many people's daily lives, Prescrire continued to do everything in its power to reliably meet healthcare professionals' informational needs, while remaining solid and financially sound, thanks in particular to effective cost control and surpluses in previous years.

Editorial costs are Prescrire's biggest expense. This expenditure enables us to produce the analyses and articles, published in *La Revue Prescrire*, that also form the basis of Prescrire's other journals (*Prescrire International* and *Compétence 4*) and its educational

programmes. The ability to work as a team, in order to provide subscribers with high-quality information that is reliable and useful to practising healthcare professionals, is a hallmark of Prescrire.

The recruitment of new subscribers is an ongoing challenge. In late August 2024, *La Revue Prescrire* had 22 236 subscribers (with or without delivery of the print journal), representing a decline in subscriber numbers. About 16 000 subscribers have opted for a subscription that includes French-language digital tools: the *Application Prescrire*, which provides access to the entire back catalogue of *La Revue Prescrire* and to our clinical pharmacology reference on drug interactions, as well as the *Guide Prescrire*, our decision support app. The number of subscriptions to these services has remained stable for several years, constituting a solid foundation on which Prescrire relies in order to evolve and grow.

**...to continue our work in support of high-quality health care.** In 2025, Prescrire remains firmly established in France's primary care landscape and is continuing its efforts to increase subscriber numbers. Despite the challenges that pervade the field of publishing, Prescrire continues to steer a steady course thanks to a shared sense of responsibility and the commitment of every member of its team. The production of information that is useful to healthcare professionals, by healthcare professionals, first and foremost in the interest of patients, is one of Prescrire's major strengths.

©Prescrire

► Excerpt from *Rev Prescrire* March 2025  
Volume 45 N° 497 • Pages 164-165

## AMP income and expenditure in fiscal year 2023-2024

